LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Viking Therapeutics Inc

Aperta

SettoreSettore sanitario

28.15 3.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.28

Massimo

29.09

Metriche Chiave

By Trading Economics

Entrata

-10M

-46M

EPS

-0.41

Dipendenti

45

EBITDA

-9.3M

-55M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+222.88% upside

Dividendi

By Dow Jones

Utili prossimi

23 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

490M

3.2B

Apertura precedente

24.73

Chiusura precedente

28.15

Notizie sul Sentiment di mercato

By Acuity

60%

40%

325 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Viking Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 apr 2025, 14:14 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

7 feb 2025, 10:30 UTC

Notizie principali

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 dic 2024, 15:04 UTC

Notizie principali

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dic 2024, 14:53 UTC

Notizie principali

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 nov 2024, 12:22 UTC

Notizie principali

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 nov 2024, 12:00 UTC

Notizie principali

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 nov 2024, 10:11 UTC

Azioni calde

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 ott 2024, 12:01 UTC

Notizie principali

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 ott 2024, 12:01 UTC

Notizie principali

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 set 2024, 13:55 UTC

Notizie principali

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 lug 2024, 15:03 UTC

Utili

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Confronto tra pari

Modifica del prezzo

Viking Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

222.88% in crescita

Previsioni per 12 mesi

Media 88.47 USD  222.88%

Alto 125 USD

Basso 30 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Viking Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

17 ratings

15

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

27.69 / 29.02Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

325 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.